UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000005219
Receipt No. R000006190
Scientific Title Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes
Date of disclosure of the study information 2011/03/08
Last modified on 2018/09/18 15:50:48

No. Disposal Last modified on Item of update
1 Insert 2011/03/08 15:39:56
2 Update 2011/08/01 09:58:32 Key inclusion criteria
3 Update 2012/08/30 18:31:53 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
4 Update 2012/08/30 18:33:00 Post marketing survey by drug manufacture etc., specified by Japanese law.
5 Update 2014/02/12 13:55:21 Target sample size
6 Update 2015/01/07 13:10:27 Recruitment status
7 Update 2017/01/10 10:02:00 Recruitment status
8 Update 2018/09/18 15:36:08 Recruitment status
Publication of results
URL related to results and publications
9 Update 2018/09/18 15:50:48 URL related to results and publications


Contact us.